Table 4.
Comparisons of secondary efficacy.
| GMGHT group (n= 61) | Placebo group (n= 66) | p value | |
|---|---|---|---|
| Change in patient's global assessment from baseline | |||
| 2nd week | -10.4 (10.8) | -1.7 (5.8) | 2.50 x 10−7 |
| 4th week | -17.4 (19.0) | -4.5 (6.6) | 3.24 x 10−6 |
| 6th week | -22.5 (20.7) | -9.0 (12.8) | 3.04 x 10−5 |
| Change in patient's pain assessment from baseline | |||
| 2nd week | -11.1 (11.0) | -2.2 (5,2) | 1.32 x 10−7 |
| 4th week | -17.5 (19.7) | -5.4 (6.6) | 2.07 x 10−5 |
| 6th week | -22.4 (21.3) | -9.6 (14.4) | 1.62 x 10−4 |
| Change in physician's global assessment from baseline | |||
| 2nd week | -13.3 (12.0) | -0.5 (6.1) | 4.67 x 10−11 |
| 4th week | -21.0 (19.4) | -1.8 (8.3) | 3.89 x 10−10 |
| 6th week | -23.8 (20.9) | -7.9 (16.9) | 6.57 x 10−6 |
| Change in pain WOMAC score from baseline | |||
| 2nd week | -2.8 (2.6) | -0.7 (1.8) | 1.45 x 10−6 |
| 4th week | -3.9 (4.0) | -1.2 (2.0) | 8.12 x 10−6 |
| 6th week | -4.5 (4.0) | -1.7 (2.4) | 6.82 x 10−6 |
| Change in stiffness WOMAC score from baseline | |||
| 2nd week | -0.2 (1.4) | -0.1 (1.3) | 0.75 |
| 4th week | -1.6 (1.6) | -0.7 (1.3) | 1.27 x 10−3 |
| 6th week | -1.6 (1.6) | -1.3 (1.7) | 0.22 |
| Change in function WOMAC score from baseline | |||
| 2nd week | -7.3 (8.6) | -1.7 (3.0) | 7.49 x 10−6 |
| 4th week | -12.8 (12.2) | -2.2 (3.3) | 7.16 x 10−9 |
| 6th week | -15.0 (12.8) | -4.2 (5.3) | 3.26 x 10−8 |
Values are presented as mean (SD) unless otherwise stated.
GMGHT: Gumiganghwal-tang, SD: standard deviation, WOMAC: the Western Ontario and McMaster Universities Arthritis Index.